Evidence map›Paper›PMID 35979387›Full record

ArticleOncoimmunology2022

PARP1 inhibition elicits immune responses against non-small cell lung cancer.

Pan Juncheng, Antoine Lafarge, Guido Kroemer, Maria Castedo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Pan JunchengEquipe 11 Labellisée Par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Paris, France.
Antoine LafargeEquipe 11 Labellisée Par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Paris, France.
Guido KroemerEquipe 11 Labellisée Par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Paris, France.
Maria CastedoEquipe 11 Labellisée Par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Paris, France.ORCID 0000-0001-6855-3451
Université Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High levels of intracellular poly(ADP-ribose) (PAR) resulting from an elevated activity of PAR polymerase-1 (PARP1) correlate with poor infiltration of non-small cell lung cancers by cytotoxic T lymphocytes and dismal patient prognosis. Preclinical experimentation now demonstrates that PARP1 inhibition in cancer cells mediates strong immunostimulatory effects.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansImmunityPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesAnticancer immune responseimmune escapemetabolismnon-small cell lung cancertumor microenvironment

Identifiers

PMID35979387
PMCPMC9377245
OpenAlexW4291018637

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.